Fiche centre
Nottingham University Hospitals NHS Trust
Nottingham — United Kingdom
Essais liés8clinical trials
VilleNottinghamlocalisation
PaysUnited Kingdomlocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT04616807
Essais cliniques associés
8| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Tacabrutideg | Cancer | Phase 1/2 | NCT05006716 | CaDAnCe-101 — A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies | RECRUITING |
| COVID-19 and Multiple Sclerosis Disease Modifying Therapies | SEP | À vérifier | NCT04863586 | COVID-19 and Multiple Sclerosis Disease Modifying Therapies | UNKNOWN |
| Mexiletine | Myopathies | À vérifier | NCT04616807 | An Observational Study in Adult Patients With Non-dystrophic Myotonic Disorders | COMPLETED |
| Cladribine Low Dose | Myasthénie | Phase 3 | NCT06463587 | Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad) | RECRUITING |
| SRP-1003 IV Infusion | Myopathies | Phase 1/2 | NCT06138743 | Study of SRP-1003 in Participants With Type 1 Myotonic Dystrophy | RECRUITING |
| Ocrelizumab Co-formulated With rHuPH20 | SEP | Phase 1 | NCT07667322 | OCARINA 3 — A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of a New Subcutaneous Formulation of Ocrelizumab in Participants With Multiple Sclerosis | ACTIVE_NOT_RECRUITING |
| The Paradise® Renal Denervation Ultrasound System | Hypertension | Non applicable | NCT02649426 | RADIANCE-HTN — A Study of the ReCor Medical Paradise System in Clinical Hypertension | ACTIVE_NOT_RECRUITING |
| Fenebrutinib | SEP | Phase 3 | NCT04544449 | FENtrepid — A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple Sclerosis | ACTIVE_NOT_RECRUITING |